Infliximab-associated fulminant hepatic failure in ulcerative colitis: a case report

• Published in: Journal of medical case reports Vol. 9; no. 217; p. 249
• Main Authors: Parra, Rogerio Serafim, Feitosa, Marley Ribeiro, Machado, Vanessa Foresto, Ramalho, Leandra Naira Zambelli, da Rocha, Jose Joaquim Ribeiro, Feres, Omar
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 30.10.2015; BioMed Central
• Subjects: Adult; Care and treatment; Case Report; Chemical and Drug Induced Liver Injury - pathology; Chemical and Drug Induced Liver Injury - therapy; Colitis, Ulcerative - drug therapy; Complications and side effects; Development and progression; Disease; Drug therapy; Female; Gastrointestinal Agents - administration & dosage; Gastrointestinal Agents - adverse effects; Humans; Infliximab; Infliximab - administration & dosage; Infliximab - adverse effects; Liver diseases; Liver Failure, Acute - chemically induced; Liver Failure, Acute - therapy; Liver Transplantation; Medical treatment; Treatment Outcome; Tumor Necrosis Factor-alpha - antagonists & inhibitors; Ulcerative colitis

Infliximab, an antibody against tumor necrosis factor alpha, is used to treat inflammatory bowel disease and has well-established efficacy and proven safety. Complications of this treatment are related to immunosuppression and include higher risk of serious infections and malignant neoplasia. Althou...